Quantum Leap Healthcare Collaborative
search

News & Announcements

Widely hailed as the future of phase II drug development, the adaptive I-SPY2 platform trial has set a new benchmark for efficiency, through innovation in trial design and clinical operations.
Close
Close
I-SPY Email List Sign-up

I-SPY News

Press Release

September 12, 2018

Advanced MRI methods tested in I-SPY 2 may improve monitoring and prediction of treatment response

I-SPY investigators lauded for ‘mammoth task’ of imaging quality control in multicenter trials

News Update

September 7, 2018

Quantum Leap Healthcare Collaborative Announces AstraZeneca's Olaparib And Durvalumab‎ For The I-SPY 2 Trial For Breast Cancer

A combination of poly (ADP-ribose) polymerase (PARP) enzyme inhibitor olaparib and anti-PD-L1 monoclonal antibody immunotherapy agent durvalumab, both from AstraZeneca, will be evaluated in I-SPY 2.

Press Release

September 6, 2018

I-SPY 2 TRIAL featuring three abstracts at ASCO's 2018 Annual Meeting

Three results from I-SPY’s adaptive trial design being showcased at ASCO 2018.

News Update

May 30, 2018

I-SPY founder Dr. Laura Esserman Honored: OncLive® To Induct the 2018 Class of Giants of Cancer Care®

OncLive® announced Dr. Laura Esserman as an inductee of the 2018 Giants of Cancer Care® recognition program.

News Update

May 26, 2018

Long-term efficacy results from the I-SPY 2 TRIAL indicate pathological complete response (pCR) is a powerful predictor for breast cancer survival

Data Presented at San Antonio Breast Cancer Symposium Show Significant and Clinically Impactful Relationship Between pCR and Event-Free Survival in High-Risk Breast Cancer.

Press Release

December 7, 2017

I-SPY 2 TRIAL predictive biomarker analysis shows promise to improve targeted therapy for high-risk breast cancers

New Data Analyses Presented at San Antonio Breast Cancer Symposium Spotlight Predictive Response to Pembrolizumab and MK-2206, and Demonstrate Improved Predictive Performance of Breast MRI

Press Release

December 7, 2017

Natera's Personalized CtDNA Technology Now Part Of I-SPY 2 TRIAL

With this new technology, the I-SPY 2 TRIAL can better help match agents, combinations, and additional targeted interventions to women with high-risk breast cancers.

Press Release

August 21, 2017

New Data From Phase 2 I-SPY 2 TRIAL Shows Improved Outcomes with Combination of Merck’s KEYTRUDA® (pembrolizumab) Plus Standard Neoadjuvant Therapy in Patients with High-Risk Breast Cancer

Data to Be Presented at 2017 ASCO Annual Meeting Include Findings in Patients with Locally Advanced Triple-Negative (TNBC) and Hormone Receptor-Positive/HER2-Negative (HR+/HER2-) Breast Cancers

Press Release

June 5, 2017

Healio Mentions I-SPY 2 Trial In "Five Updates For Triple Negative Breast Cancer Day"

In conjunction with Triple Negative Breast Cancer Day, HemOnc Today presents five updates in the treatment of triple-negative breast cancer and on associated disparities that may impact your practice.

News Update

March 3, 2017

Oncology Nursing News Mentions I-SPY Trials In New Agents, Combinations Showing Durable Benefit In Triple-Negative Breast Cancer

The triple-negative breast cancer (TNBC) pipeline is transforming, experts say, with the potential additions of immunotherapy and PARP inhibitors.

News Update

February 24, 2017

Anti-HER3 Monoclonal Antibody Patritumab Selected for I-SPY 2 TRIAL in Breast Cancer

A new treatment arm of the I-SPY2 TRIAL will include patritumab, an investigational anti-HER3 monoclonal antibody

Press Release

October 25, 2016